Akero Therapeutics, Inc. (AKRO)

22,11 +2,45 (+12,46%) Al cierre: 04:00PM EDT

Akero Therapeutics, Inc.

601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
650 487 6488
https://akerotx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 55

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Andrew Cheng M.D., Ph.D.	President, CEO & Director	1,04M	15,28M	1967
Dr. Jonathan M. Young J.D., Ph.D.	Co-Founder, Executive VP, COO & Secretary	672,35k	584,34k	1970
Dr. Timothy Rolph	Co-Founder & Chief Scientific Officer	722,32k	2,16M	1954
Mr. William R. White J.D.	Executive VP, CFO, Treasurer & Head of Corporate Development	678,06k	839,84k	1973
Ms. Catriona Yale	Executive VP & Chief Development Officer	678,06k	458,9k	1972
Mr. Scott A. Gangloff	Chief Technology Officer	N/A	N/A	1974
Mr. Patrick Lamy	Senior Vice President of Commercial Strategy	N/A	N/A	1973
Mr. John J. Schembri	VP of Finance & Controller	N/A	N/A	1962

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de Akero Therapeutics, Inc., a día 1 de mayo de 2024, es 9. Las puntuaciones base son Auditoría: 9; Tablero: 9; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.